Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spirulina-Derived Product for Oral Mucositis in Head and Neck Cancer Radiotherapy
NCT07040969Phase 2Active, not recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2025
- Primary completion
- Jan 2026
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in oral mucositis (OM) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Incidence of severe oral mucositis (WHO grade >=3) at 14.5 weeks. Started Jun 2025; status: active, not recruiting.
02
Conditions
oral mucositis (OM)
Beyond the preview
Go deeper on NCT07040969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07040969.